SCHEMBL3756642

SCHEMBL3756642

Cc1conc1C(=O)Nc1[c]cccc1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RIPK1 Q13546 1/20 0.35
NPC1 O15118 6/20 0.33
RAB9A P51151 6/20 0.33
TAS1R3 Q7RTX0 1/20 0.33
TAS1R1 Q7RTX1 1/20 0.33
TAS1R2 Q8TE23 1/20 0.33
KMT2A Q03164 4/20 0.32
SMN1; SMN2 Q16637 3/20 0.32
MEN1 O00255 3/20 0.32
L3MBTL1 Q9Y468 2/20 0.32
HTT P42858 2/20 0.32
LMNA P02545 1/20 0.32
PKM P14618 1/20 0.32
ALDH1A1 P00352 2/20 0.32
HPGD P15428 2/20 0.32
PTGS2 P35354 1/20 0.32
HIF1A Q16665 1/20 0.31
ATR Q13535 2/20 0.31
PRKDC P78527 1/20 0.31
NAMPT P43490 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL482522 0.73 HPGD (0.57) NPC1RAB9ASMN1; SMN2L3MBTL1HTT
SCHEMBL3759873 0.72 SMN1; SMN2 (0.41) NPC1RAB9AKMT2ASMN1; SMN2MEN1
SCHEMBL25458161 0.70 BAZ2B (0.38) NPC1KMT2ASMN1; SMN2MEN1HTT
SCHEMBL7641330 0.70 NPC1 (0.53) NPC1RAB9ASMN1; SMN2L3MBTL1LMNA
SCHEMBL6033544 0.69 SMN1; SMN2 (0.38) NPC1RAB9AKMT2ASMN1; SMN2MEN1
SCHEMBL429187 0.69 PTPN1 (0.48) NPC1RAB9AKMT2ASMN1; SMN2MEN1
SCHEMBL3759725 0.69 EGLN2 (0.49) NPC1RAB9AKMT2AMEN1ALDH1A1
SCHEMBL97108 0.68 HSD17B10 (0.48) NPC1RAB9AKMT2ASMN1; SMN2MEN1
SCHEMBL27735271 0.68 EGLN1 (0.56) KMT2AMEN1ALDH1A1GRM5
SCHEMBL9725165 0.68 SMN1; SMN2 (0.44) NPC1RAB9AKMT2ASMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2029570-B1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA SA (BE) 2014-10-15 EP disclosed
US-8324204-B2 Fused thiophene derivatives as kinase inhibitors UCB PHARMA SA (BE) 2012-12-04 US disclosed
US-20100305066-A1 Fused Thiophene Derivatives as Kinase Inhibitors UCB PHARMA S.A. (BE) 2010-12-02 US disclosed
WO-2009122148-A1 FUSED THIOPHENE AND THIAZOLE DERIVATIVES AS PI3K KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-10-08 WO disclosed
WO-2009071895-A1 FUSED THIAZOLE AND THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-06-11 WO disclosed
WO-2009071890-A1 TRICYCLIC KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-06-11 WO disclosed
EP-2029570-A1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB Pharma S.A. (BE) 2009-03-04 EP disclosed
WO-2007141504-A1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2007-12-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305066-A1 Fused Thiophene Derivatives as Kinase Inhibitors PIKFYVE, PI4KA, PIK3CA RIPK1 266/4885NPC1 3855/4885RAB9A 713/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.